COMMUNIQUÉS West-GlobeNewswire

-
Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates
28/05/2025 -
genXtraits Inc. expands collaboration with The New Zealand Institute for Plant & Food Research Limited to increase vitamin C in crops, including corn and soybean
28/05/2025 -
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
28/05/2025 -
Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method
28/05/2025 -
Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2025 Results
28/05/2025 -
4DMT to Participate in Upcoming Investor Conferences
28/05/2025 -
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
28/05/2025 -
SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy
28/05/2025 -
Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology
28/05/2025 -
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
28/05/2025 -
Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference
28/05/2025 -
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
28/05/2025 -
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
28/05/2025 -
Vittoria Biotherapeutics to Share Trials-in-Progress Presentation from Phase 1 Study of VIPER-101 at ASCO 2025 Annual Meeting
28/05/2025 -
iTeos Therapeutics Announces Its Intention to Wind Down Operations
28/05/2025 -
Alpha Tau to Present at Jefferies Global Healthcare Conference
28/05/2025 -
HCVC leads kyron.bio €5.5M round to use glycan engineering for advanced drug design
28/05/2025 -
Flare Therapeutics to Participate in Jefferies Global Healthcare Conference
28/05/2025 -
Immunotherapeutic Targets for Recurrent Medulloblastoma Receives $85K Grant from Brain Cancer Canada
28/05/2025
Pages